Yun Gong
Executive Director, Strategic Partnerships & General Manager, Platform Innorna
Seminars
Wednesday 22nd July 2026
Engineering Targeted mRNA-LNPs to Enable In Vivo Immunotherapy for Autoimmune Diseases
12:20 pm
- NHP data demonstrating the potential of targeted mRNA-LNPs to enable in vivo immunotherapy for autoimmune disease models
- Robust B-cell depletion across peripheral blood, spleen, and lymphoid tissues using a proprietary targeted LNP delivery platform
- Evidence of immune-reset biology with emerging safety and tolerability supporting continued pre-clinical development
